1-(2,6-Dibenzyloxybenzoyl)-3-(9H-fluoren-9-yl)-urea: A novel cyclophilin A allosteric activator

Biochemical and Biophysical Research Communications

Volumn 425, Issue 4, 2012, Pages 938-943

  Lv, Maosheng ^a   Shi, Ting ^b   Mao, Xiaona ^a   Li, Xi ^a   Chen, Yingyi ^b   Zhu, Jin ^a   Ni, Shuaishuai ^a   Shen, Xu ^a,c   Jiang, Hualiang ^a,c   Li, Jian ^a   Zhang, Jian ^b   Huang, Jin ^a  

^a EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Allosteric activator; Chemical tool; CypA; PPIase activity

Indexed keywords

1 (2,6 DIBENZYLOXYBENZOYL) 3 (9H FLUOREN 9 YL)UREA; CYCLOPHILIN A; UNCLASSIFIED DRUG; UREA DERIVATIVE;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; BINDING SITE; CATALYSIS; DRUG BINDING; DRUG SCREENING; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; MOLECULAR DYNAMICS; PRIORITY JOURNAL; SIMULATION;

ALLOSTERIC REGULATION; BINDING SITES; CELL LINE; CYCLOPHILIN A; ENZYME ACTIVATION; FLUORENES; HUMANS; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; UREA;

EID: 84865999761     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.08.014     Document Type: Article

References (31)

1. Handschumacher R.E., Harding M.W., Rice J., Drugge R.J., Speicher D.W. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 1984, 226:544-547.
2. Fischer G., Tradler T., Zarnt T. The mode of action of peptidyl prolyl cis/trans isomerases in vivo: binding vs. catalysis. FEBS Lett. 1998, 426:17-20.
3. Fischer G., Bang H. The refolding of urea-denatured ribonuclease A is catalyzed by peptidyl-prolyl cis-trans isomerase. Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol. 1985, 828:39-42.
4. Colgan J., Asmal M., Neagu M., Yu B., Schneidkraut J., Lee Y., Sokolskaja E., Andreotti A., Luban J. Cyclophilin A regulates tcr signal strength in CD4+ T Cells via a proline-directed conformational switch in Itk. Immunity 2004, 21:189-201.
5. Galat A. Peptidylproline cis-trans-isomerases: immunophilins. Eur. J. Biochem. 1993, 216:689-707.
6. Kofron J.L., Kuzmic P., Kishore V., Colon-Bonilla E., Rich D.H. Determination of kinetic constants for peptidyl prolyl cis-trans isomerases by an improved spectrophotometric assay. Biochemistry 1991, 30:6127-6134.
7. Arora K., Gwinn W.M., Bower M.A., Watson A., Okwumabua I., MacDonald H.R., Bukrinsky M.I., Constant S.L. Extracellular cyclophilins contribute to the regulation of inflammatory responses. J. Immunol. 2005, 175:517-522.
8. Harigai M., Hara M., Takahashi N., Kitani A., Hirose T., Suzuki K., Kawakami M., Hidaka T., Kawaguchi Y., Ishizuka T. Presence of autoantibodies to peptidyl-prolyl cis-trans isomerase (cyclosporin A-binding protein) in systemic lupus erythematosus. Clin. Immunol. Immunopathol. 1992, 63:58-65.
9. Luban J., Bossolt K.L., Franke E.K., Kalpana G.V., Goff S.P. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 1993, 73:1067.
10. Franke E.K., Yuan H.E.H., Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 1994, 372:359-362.
11. Goto K., Watashi K., Inoue D., Hijikata M., Shimotohno K. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. Cancer Sci. 2009, 100:1943-1950.
12. Göldner F.M., Patrick J.W. Neuronal localization of the cyclophilin A protein in the adult rat brain. J. Comp. Neurol. 1996, 372:283-293.
13. Georgantas R.W., Tanadve V., Malehorn M., Heimfeld S., Chen C., Carr L., Martinez-Murillo F., Riggins G., Kowalski J., Civin C.I. Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. Cancer Res. 2004, 64:4434.
14. Borrel F., Feurer C., Gubler H., Staehelin H. Biological effects of cyclosporine A: a new antilymphocyte agent. Agents Actions 1976, 6:468.
15. André N., Roquelaure B., Conrath J. Molecular effects of cyclosporine and oncogenesis: a new model. Med. Hypotheses 2004, 63:647-652.
16. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin. Transplant. 1998, 147.
17. Mori T., Itami S., Yanagi T., Tatara Y., Takamiya M., Uchida T. Use of a real-time fluorescence monitoring system for high-throughput screening for prolyl isomerase inhibitors. J. Biomol. Screening 2009, 14:419-424.
18. Daum S., Schumann M., Mathea S., Aumüller T., Balsley M.A., Constant S.L., de Lacroix B.F., Kruska F., Braun M., Schiene-Fischer C. Isoform-specific inhibition of cyclophilins. Biochemistry 2009, 48:6268-6277.
19. Ni S., Yuan Y., Huang J., Mao X., Lv M., Zhu J., Shen X., Pei J., Lai L., Jiang H. Discovering potent small molecule inhibitors of cyclophilin A using de novo drug design approach. J. Med. Chem. 2009, 52:5295-5298.
20. Howard B.R., Vajdos F.F., Li S., Sundquist W.I., Hill C.P. Structural insights into the catalytic mechanism of cyclophilin A. Nat. Struct. Biol. 2003, 10:475-481.
21. Friesner R.A., Banks J.L., Murphy R.B., Halgren T.A., Klicic J.J., Daniel T., Repasky M.P., Knoll E.H., Shelley M., Perry J.K. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47:1739-1749.
22. Halgren T.A., Murphy R.B., Friesner R.A., Beard H.S., Frye L.L., Pollard W.T., Banks J.L. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 2004, 47:1750-1759.
23. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998, 19:1639-1662.
24. Huang Z., Zhu L., Cao Y., Wu G., Liu X., Chen Y., Wang Q., Shi T., Zhao Y., Wang Y., Li W., Li Y., Chen H., Chen G., Zhang J. ASD: a comprehensive database of allosteric proteins and modulators. Nucleic Acids Res. 2011, 39:D663-669.
25. Wang J., Cieplak P., Kollman P.A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules?. J. Comput. Chem. 2000, 21:1049-1074.
26. Bayly C.I., Cieplak P., Cornell W., Kollman P.A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: the RESP model. J. Phys. Chem. 1993, 97:10269-10280.
27. Ryckaert J.P., Ciccotti G., Berendsen H.J.C. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J. Comput. Phys. 1977, 23:327-341.
28. Miyamoto S., Kollman P.A. SETTLE: an analytical version of the SHAKE and RATTLE algorithm for rigid water models. J. Comput. Chem. 1992, 13:952-962.
29. Berendsen H.J.C., Postma J.P.M., Van Gunsteren W.F., DiNola A., Haak J. Molecular dynamics with coupling to an external bath. J. Chem. Phys. 1984, 81:3684.
30. Boulos S., Meloni B.P., Arthur P.G., Majda B., Bojarski C., Knuckey N.W. Evidence that intracellular cyclophilin A and cyclophilin A/CD147 receptor-mediated ERK1/2 signalling can protect neurons against in vitro oxidative and ischemic injury. Neurobiol. Dis. 2007, 25:54-64.
31. Hamelberg D., McCammon J.A. Mechanistic insight into the role of transition-state stabilization in cyclophilin A. J. Am. Chem. Soc. 2008, 131:147-152.